Morning Briefing
Summaries of health policy coverage from major news organizations
Covid BQ.1 Variant Rising: Now Constitutes 10% Of US Cases
The CDC had previously bundled BQ.1 and BQ.1.1 with their shared parent BA.5 in the agency's weekly "Nowcast" estimates. BQ.1 was first named by scientists in early September, based on sequences spotted across the U.S. and several other countries. (Tin, 10/14)
Concern is rapidly growing over emerging omicron coronavirus variant BQ.1 and its sibling BQ.1.1, which experts say appear to be strong candidates for a winter surge in the U.S. and could knock the BA.5 variant out of its dominant spot. (Hwang, 10/16)
If you already got your omicron-specific Covid booster, you might have experienced some side effects. Maybe even ones that were more intense than your previous shot. But there鈥檚 no need to worry: Experts and new data say the new shots appear to work 鈥 regardless of whether you experience moderate, mild or no side effects at all. (Constantino, 10/15)
In related news about covid research 鈥
Anthony Fauci praised Operation Warp Speed, former President Donald Trump鈥檚 campaign to quickly create a Covid-19 vaccine, as 鈥渁 very positive thing鈥 in an interview Sunday. But what, host Jonathan Karl asked, about the idea that many Trump supporters continue to constitute a majority of the anti-vaccine movement anyway? (Olander, 10/16)
In related news about covid research 鈥
Chronic fatigue syndrome and long Covid are both part of a much larger group of illnesses that arise after a viral, or sometimes bacterial, infection. Mononucleosis, HIV, Lyme, Ebola, Sars and many other infections can also have similarly prolonged effects. But experts say attention, funding and research into these post-infectious illnesses has historically been limited, and patients have often had their symptoms minimized or dismissed. Long Covid has changed that. (Root, 10/17)
As the coronavirus pandemic was upending daily life across the globe in early 2020, government officials challenged scientists to swiftly develop accurate and easy-to-use tests for COVID-19. It was a break in the traditional slog from idea to marketable medical tool. The effort, which included funding and support, proved so successful that it鈥檚 now a format for a new initiative funded by the National Institutes of Health. (Cohn, 10/17)